https://www.tctmd.com/news/some-surprises-low-risk-tavi-follow-partner-3-and-evolut-trials
0
0
10/24/23 at 8:00pm
Organization
TCTMD
Author
Michael O'Riordan
(UPDATED) TAVI benefits were attenuated and mortality trended higher in PARTNER 3 at 5 years. For Evolut, TAVI maintained an edge.
Create an account
or login to join the discussion